MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
about
A stochastic model of oncogene expression and the relevance of this model to cancer therapy.Hsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaTen things you should know about protein kinases: IUPHAR Review 14Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsDiscovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsBPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cellsIntracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cellsTrough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.ABCB1 genetic variants in leukemias: current insights into treatment outcomesDevelopment of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyPractical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateWnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.The pharmacogenetics of imanitib.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.Monitoring response and resistance to treatment in chronic myeloid leukemia.ABCG2: a perspective.The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.Pharmacotherapy of gastrointestinal stromal tumours.Pharmacophore-based discovery of ligands for drug transporters.Cancer treatment with kinase inhibitors: what have we learnt from imatinib?Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinCancer stem cells: are we missing the target?Cancer Stem Cells: From Bench to BedsidePopulation pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesMolecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.Sarcomas and pharmacogenetics.
P2860
Q25256645-CD620344-730B-486E-83DE-9A976FAE2B91Q26771790-D26D0BF8-2F32-4F80-8DE5-8C3DA1CF32BCQ26849417-3703E55F-3286-469C-9835-1A9857611768Q26849792-938A7530-F17D-4814-AE55-A0F48B6044EDQ27660281-3EEF8003-620F-41DE-9463-161F2F6FCEB8Q28476664-1842BF34-7CFD-4301-AC77-9CB1AE4CFF81Q28481327-D9789D24-D006-432F-9780-DFE5AC7923D8Q33394772-00924BBC-2E41-4860-B3B0-8979B10B76F2Q33566582-0BEC6B24-834A-4328-88D8-03EEBD12100AQ33707782-3A26C2F8-0128-4A0C-8AD6-1AB74534C7E1Q33726782-C20D7642-F923-4BD8-BF96-DB92B7919A3DQ33747277-3FE9138D-1293-4B6E-B3AC-3A62DB6C0557Q33828409-177FE992-3C30-468A-BD8E-2BA039795010Q33878636-314462DC-7F8E-4BD2-B640-D997B94DD6C2Q34016866-A4A73CB9-1A4C-4B35-84B8-2BAAECFCCB60Q34183433-F1AE6FB9-8A6A-45E9-A725-236729B339B1Q34184723-9C6271A9-722D-468E-BBBB-099C8AD9750EQ34348134-49763CD1-35BC-406B-A3D8-409955A679AFQ34469295-C23F4D20-D3AC-47CB-8A9C-77882C5D4E96Q34636081-BFB62C2C-8989-4C8F-A1F0-2FA35F74C342Q34761663-8DC15574-70C3-4891-986B-C3B1AE39860CQ35016817-353534FF-4512-4468-8251-1C41AD87FE83Q35026699-359F62F7-7B67-4863-988E-175C744A05E1Q35036482-57F4AF03-DBB5-4129-91B1-E967DDD963F5Q35037415-3FE6D2D9-FE90-45B2-8303-95D1C8338CF2Q35141800-BF701C5F-C014-4F49-8EC5-ACCBAC857C3DQ35143939-FDD1A668-A01C-4166-AB62-645B9463A5F1Q35594214-C62B2844-A3AB-4A60-837C-896FE59C07A4Q35622440-8C1B7C64-8ADF-4A68-8F6E-86FB91D627E3Q35708124-BD62E43A-1830-45C5-9032-DD868A1BFCFCQ35717808-82DFBDCD-12F0-4D89-9F77-5826140409DDQ35752241-7690883D-4D05-45C9-B49C-2CE6DE6B5A71Q35765724-D01D0284-49B8-4AAB-BA51-7C3280242DCCQ35827616-BF251906-4EBD-4DB2-871C-CF63BE1DAD5AQ35905629-B0DB2CF8-678E-43FF-8274-4DD6E6861A1DQ35946822-52C30B06-2EAF-4D66-B79F-4E568595C4E1Q35991845-57280F6D-4E32-4797-A717-685F2EEFE365Q36106559-100DAD9C-4E57-42CA-9626-D6E604BE6E80Q36184500-31A961EC-ECAB-4BCB-8E69-7B68AEADCADFQ36249224-2C9D3442-9D0C-4DCF-BFB9-206D70D123C0
P2860
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
MDR1 gene overexpression confe ...... in leukemia cell line models.
@en
type
label
MDR1 gene overexpression confe ...... in leukemia cell line models.
@en
prefLabel
MDR1 gene overexpression confe ...... in leukemia cell line models.
@en
P2093
P1433
P1476
MDR1 gene overexpression confe ...... in leukemia cell line models.
@en
P2093
Claudine Chollet
Francis Belloc
François Moreau-Gaudry
François-Xavier Mahon
John M Goldman
Josy Reiffers
Junia V Melo
Valérie Lagarde
P304
P356
10.1182/BLOOD.V101.6.2368
P407
P577
2003-03-01T00:00:00Z